3,0
7. Jän. 2015
Mitarbeiter (anonym)
Ehemaliger Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Diversity in Oncology portfolio, very strong in oncology.
Kontras
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.